ASN, HHS name KidneyX Summit winners
Click Here to Manage Email Alerts
Key takeaways:
- The KidneyX Summit is a public-private partnership between the American Society of Nephrology and HHS.
- Members of regenerative medicine, cellular engineering and related specialties competed in the contest.
The American Society of Nephrology and HHS awarded $9.2 million to eight winners of the Artificial Kidney Prize Phase 2 Kidney Innovation Accelerator KidneyX Summit.
“Kidney diseases are common, serious and deadly,” John R. Sedor, MD, FASN, steering committee chair of KidneyX, said in a press release. “People with kidney diseases have demanded innovative treatment technologies and management strategies to replace dialysis, which has changed slowly and incrementally over 50 years. The nephrology scientific community has responded with a pipeline of discoveries that promise to revolutionize kidney care. The Artificial Kidney Prize Phase 2 winners highlight paradigm shifting solutions in xenotransplantation and regenerative medicine that are being developed to reduce the burdens of kidney disease.”
The KidneyX summit is a public-private partnership between ASN and HHS that recognizes novel approaches to developing a bioartificial kidney. The competition was divided into two tracks, with two track 1 contestants receiving $1.6 million each and six track 2 applicants both winning $1 million.
Members of the regenerative medicine, cellular engineering, tissue engineering, systems biology and synthetic biology specialties focused on the development of prototype bioartificial kidneys or creation of new tools to help develop bioartificial kidneys, according to the release.
“Patients with renal failure experience not only the impact of their disease but the inevitable side effects of existing treatments because transplant organs are only available for a few lucky recipients,” Harald Ott, the founder and CEO of IVIVA Medical, and one of the track 2 winners, said in a company press release.
Ott’s winning entry was titled “Manufacturing and system dynamics tools enabling autonomous blood purification implants,” which are built from patient-derived cells.
The other track 2 winners included Anthony Atala, MD, with 3D vascularized biomimetic renal construct platform for accelerated vascular integration; William Chang, MD, PhD, for Engineering bioartificial kidneys: Combining kidney organoids and peritoneal dialysis; Nils Olof Lindström, PhD, for Draining artificial kidneys by connecting synchronized nephrons to synthetic organizers; Shuvo Roy, PhD, for Immunoprotective bioreactor for kidney cell encapsulation; and Ben Shepherd, PhD, for Bioengineered therapies for patients with kidney failure. Track one winners were David K.C. Cooper, MD, PhD, FRCS, with Alemtuzumab induction therapy in monkeys with life-supporting pig kidney transplants; and Matt Tector, PhD, for Renal Xenograft Phase 2: Solving the donor kidney shortage.
Reference:
IVIVA Medical Wins KidneyX Prize for Advanced Organ Therapeutics to Cure Renal Failure. https://www.prnewswire.com/news-releases/iviva-medical-wins-kidneyx-prize-for-advanced-organ-therapeutics-to-cure-renal-failure-301847899.html. Accessed June 12, 2023.
Read more about
Click Here to Manage Email Alerts